Journal
SCIENCE CHINA-LIFE SCIENCES
Volume 59, Issue 4, Pages 360-369Publisher
SCIENCE PRESS
DOI: 10.1007/s11427-016-5025-6
Keywords
solid tumor; adoptive cell therapy; T cell; chimeric antigen receptor
Categories
Funding
- Supporting Programs of Research Fund of State Key Laboratory of Oncogenes and Related Genes [91-14-12]
- Shanghai Science and Technology Development Funds [12JC1408300]
- Shanghai Rising-Star Program (A type) [13QA1403300]
- One Hundred Talents Scientific Research Projects of Health Systems in Shanghai [XBR2013123]
Ask authors/readers for more resources
Chimeric antigen receptors (CARs) are artificial recombinant receptors that generally combine the antigen-recognition domain of a monoclonal antibody with T cell activation domains. Recent years have seen great success in clinical trials employing CD19-specific CAR-T cell therapy for B cell leukemia. Nevertheless, solid tumors remain a major challenge for CAR-T cell therapy. This review summarizes the preclinical and clinical studies on the treatment of solid tumors with CAR-T cells. The major hurdles for the success of CAR-T and the novel strategies to address these hurdles have also been described and discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available